Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CROLOM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CROLOM.
ACUVUE THERAVISION WITH KETOTIFEN vs CROLOM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Mast Cell Stabilizer